A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)

Inclusion Criteria: * Cytologically or histologically confirmed diagnosis of Stage IV NSCLC as defined by the American Joint Committee on Cancer Staging Criteria for Lung Cancer (AJCC 7th edition 2009). * Eligible for first-line treatment with erlotinib based on documented evidence of tumor harboring an activating EGFR mutation \[exon 19 deletion or exon 21 (L858R) substitution mutation\]. * Mandatory provision of adequate archived stage IV NSCLC tissue samples or tissue samples other than stage IV NSCLC may be acceptable (optional for part C). * At least one measurable lesion. * Life expectancy of at least 3 months. Exclusion Criteria: * Known T790M EGFR mutation (not applicable for Part C Period 2). * Known leptomeningeal carcinomatosis, uncontrolled/unstable spinal cord compression, or brain metastases. * Serious illness or medical condition. * Ongoing treatment with CYP3A4 inducers or strong inhibitors. * Ongoing therapy with nonsteroidal anti-inflammatory drugs for more than 2 months. * History of gross hemoptysis. * Significant bleeding disorders. * Radiologically documented evidence of major blood vessel invasion or encasement by cancer. * Radiographic evidence of intratumor cavitation. * History of gastrointestinal perforation within last 6 months. * History of bowel obstruction, inflammatory enteropathy or extensive intestinal resection. * History of any arterial thrombotic event within 6 months prior to enrollment. * The participant has any known significant ophthalmologic abnormalities of the surface of the eye.